Keros Therapeutics (NASDAQ:KROS) Cut to “Neutral” at Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Keros Therapeutics (NASDAQ:KROS) from an overweight rating to a neutral rating in a research note released on Tuesday, Marketbeat reports. Cantor Fitzgerald also issued estimates for Keros Therapeutics’ FY2025 earnings at ($5.82) EPS.

A number of other equities research analysts also recently issued reports on KROS. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Wells Fargo & Company boosted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Truist Financial reduced their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, HC Wainwright reduced their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $12.02 on Tuesday. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00. The business has a fifty day moving average price of $33.12 and a 200 day moving average price of $46.51. The company has a market cap of $486.93 million, a P/E ratio of -2.31 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.33) EPS. As a group, sell-side analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after purchasing an additional 179,374 shares during the period. Alkeon Capital Management LLC grew its position in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. raised its holdings in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP increased its position in shares of Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.